Tuberculosis of other urinary organs
ICD-10 A18.13 is a billable code used to indicate a diagnosis of tuberculosis of other urinary organs.
Tuberculosis of other urinary organs refers to the infection caused by Mycobacterium tuberculosis affecting parts of the urinary system that are not the kidneys or bladder. This condition can manifest in various forms, including renal tuberculosis, which primarily affects the kidneys, but can also involve the ureters, urethra, and other urinary structures. Symptoms may include hematuria (blood in urine), dysuria (painful urination), and flank pain. Diagnosis typically involves a combination of clinical evaluation, imaging studies such as ultrasound or CT scans, and microbiological tests including urine cultures and PCR testing for Mycobacterium tuberculosis. Treatment usually consists of a multi-drug regimen over an extended period, often involving isoniazid, rifampicin, pyrazinamide, and ethambutol. Monitoring for drug resistance is crucial, as resistance can complicate treatment and prolong recovery. Public health implications are significant, as tuberculosis is a communicable disease, necessitating contact tracing and isolation procedures for active cases to prevent transmission. Regular follow-up and adherence to treatment protocols are essential to ensure successful outcomes and minimize the risk of drug-resistant strains.
Detailed documentation of diagnostic tests, treatment plans, and follow-up care.
Patients presenting with urinary symptoms and a history of tuberculosis exposure.
Consideration of drug resistance patterns and the need for specialized treatment regimens.
Comprehensive records of imaging studies, surgical interventions, and pathology reports.
Management of urinary tract symptoms in patients with a known history of tuberculosis.
Awareness of the potential for surgical intervention in severe cases.
Used to confirm the presence of Mycobacterium tuberculosis in urine samples.
Document the reason for the culture and any prior treatments.
Infectious disease specialists should ensure comprehensive testing for drug resistance.
Common symptoms include hematuria, dysuria, flank pain, and urinary frequency. Patients may also experience systemic symptoms such as fever and weight loss.
Diagnosis typically involves urine cultures, imaging studies, and clinical evaluation. PCR testing may also be used to detect Mycobacterium tuberculosis.
Treatment usually involves a multi-drug regimen including isoniazid, rifampicin, pyrazinamide, and ethambutol, with close monitoring for drug resistance.
